69 related articles for article (PubMed ID: 28951092)
1. Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.
Ishibashi D; Ishikawa T; Mizuta S; Tange H; Nakagaki T; Hamada T; Nishida N
Neurotherapeutics; 2020 Oct; 17(4):1836-1849. PubMed ID: 32767031
[TBL] [Abstract][Full Text] [Related]
2. Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.
Ferreira NC; Marques IA; Conceição WA; Macedo B; Machado CS; Mascarello A; Chiaradia-Delatorre LD; Yunes RA; Nunes RJ; Hughson AG; Raymond LD; Pascutti PG; Caughey B; Cordeiro Y
PLoS One; 2014; 9(1):e84531. PubMed ID: 24400098
[TBL] [Abstract][Full Text] [Related]
3. Methionine oxidation within the prion protein.
Bettinger J; Ghaemmaghami S
Prion; 2020 Dec; 14(1):193-205. PubMed ID: 32744136
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Drug Discovery for Prion Disease Using a Novel Binding Simulation.
Ishibashi D; Nakagaki T; Ishikawa T; Atarashi R; Watanabe K; Cruz FA; Hamada T; Nishida N
EBioMedicine; 2016 Jul; 9():238-249. PubMed ID: 27333028
[TBL] [Abstract][Full Text] [Related]
5. Definable equilibrium states in the folding of human prion protein.
Hosszu LL; Wells MA; Jackson GS; Jones S; Batchelor M; Clarke AR; Craven CJ; Waltho JP; Collinge J
Biochemistry; 2005 Dec; 44(50):16649-57. PubMed ID: 16342955
[TBL] [Abstract][Full Text] [Related]
6. Application of the fragment molecular orbital method to discover novel natural products for prion disease.
Choi J; Kim HJ; Jin X; Lim H; Kim S; Roh IS; Kang HE; No KT; Sohn HJ
Sci Rep; 2018 Aug; 8(1):13063. PubMed ID: 30166585
[TBL] [Abstract][Full Text] [Related]
7. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP.
Rambold AS; Miesbauer M; Rapaport D; Bartke T; Baier M; Winklhofer KF; Tatzelt J
Mol Biol Cell; 2006 Aug; 17(8):3356-68. PubMed ID: 16707568
[TBL] [Abstract][Full Text] [Related]
8. Functional genomics screen identifies proteostasis targets that modulate prion protein (PrP) stability.
Abrams J; Arhar T; Mok SA; Taylor IR; Kampmann M; Gestwicki JE
Cell Stress Chaperones; 2021 Mar; 26(2):443-452. PubMed ID: 33547632
[TBL] [Abstract][Full Text] [Related]
9. Multimodal small-molecule screening for human prion protein binders.
Reidenbach AG; Mesleh MF; Casalena D; Vallabh SM; Dahlin JL; Leed AJ; Chan AI; Usanov DL; Yehl JB; Lemke CT; Campbell AJ; Shah RN; Shrestha OK; Sacher JR; Rangel VL; Moroco JA; Sathappa M; Nonato MC; Nguyen KT; Wright SK; Liu DR; Wagner FF; Kaushik VK; Auld DS; Schreiber SL; Minikel EV
J Biol Chem; 2020 Sep; 295(39):13516-13531. PubMed ID: 32723867
[TBL] [Abstract][Full Text] [Related]
10. The N-terminus of the prion protein is a toxic effector regulated by the C-terminus.
Wu B; McDonald AJ; Markham K; Rich CB; McHugh KP; Tatzelt J; Colby DW; Millhauser GL; Harris DA
Elife; 2017 May; 6():. PubMed ID: 28527237
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides.
Reidenbach AG; Minikel EV; Zhao HT; Guzman SG; Leed AJ; Mesleh MF; Kordasiewicz HB; Schreiber SL; Vallabh SM
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861275
[TBL] [Abstract][Full Text] [Related]
12. A mechanism for copper inhibition of infectious prion conversion.
Cox DL; Pan J; Singh RR
Biophys J; 2006 Jul; 91(2):L11-3. PubMed ID: 16698781
[TBL] [Abstract][Full Text] [Related]
13. Binding modes of potential anti-prion phytochemicals to PrP
Neupane S; Khadka J; Rayamajhi S; Pandey AS
J Ayurveda Integr Med; 2023; 14(4):100750. PubMed ID: 37453159
[TBL] [Abstract][Full Text] [Related]
14. Toward the Atomic Structure of PrP
Rodriguez JA; Jiang L; Eisenberg DS
Cold Spring Harb Perspect Biol; 2017 Sep; 9(9):. PubMed ID: 28096267
[TBL] [Abstract][Full Text] [Related]
15. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).
Chessum NEA; Sharp SY; Caldwell JJ; Pasqua AE; Wilding B; Colombano G; Collins I; Ozer B; Richards M; Rowlands M; Stubbs M; Burke R; McAndrew PC; Clarke PA; Workman P; Cheeseman MD; Jones K
J Med Chem; 2018 Feb; 61(3):918-933. PubMed ID: 29240418
[TBL] [Abstract][Full Text] [Related]
16. Poly-L-histidine inhibits prion propagation in a prion-infected cell line.
Honda R; Yamaguchi KI; Elhelaly AE; Fuji M; Kuwata K
Prion; 2018; 12(3-4):226-233. PubMed ID: 30074430
[TBL] [Abstract][Full Text] [Related]
17. The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrP
Pagadala NS; Bjorndahl TC; Joyce M; Wishart DS; Syed K; Landi A
Bioorg Med Chem; 2017 Oct; 25(20):5875-5888. PubMed ID: 28951092
[TBL] [Abstract][Full Text] [Related]
18. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
19. The charge structure of helix 1 in the prion protein regulates conversion to pathogenic PrPSc.
Norstrom EM; Mastrianni JA
J Virol; 2006 Sep; 80(17):8521-9. PubMed ID: 16912302
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
